227 related articles for article (PubMed ID: 18663728)
1. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
5. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
[TBL] [Abstract][Full Text] [Related]
7. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
8. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
9. Androgen-independent prostate cancer progression in the TRAMP model.
Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
[TBL] [Abstract][Full Text] [Related]
10. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
11. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
[TBL] [Abstract][Full Text] [Related]
12. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
13. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice.
Fritz WA; Lin TM; Cardiff RD; Peterson RE
Carcinogenesis; 2007 Feb; 28(2):497-505. PubMed ID: 17052998
[TBL] [Abstract][Full Text] [Related]
14. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.
Leman ES; Madigan MC; Brünagel G; Takaha N; Coffey DS; Getzenberg RH
J Cell Biochem; 2003 Feb; 88(3):599-608. PubMed ID: 12532335
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
16. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A
Cancer Res; 2001 Sep; 61(18):6777-82. PubMed ID: 11559550
[TBL] [Abstract][Full Text] [Related]
17. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD
Carcinogenesis; 2008 Jan; 29(1):120-8. PubMed ID: 17942462
[TBL] [Abstract][Full Text] [Related]
18. Chinese medicinal herb Scutellaria barbata modulates apoptosis and cell survival in murine and human prostate cancer cells and tumor development in TRAMP mice.
Wong BY; Nguyen DL; Lin T; Wong HH; Cavalcante A; Greenberg NM; Hausted RP; Zheng J
Eur J Cancer Prev; 2009 Aug; 18(4):331-41. PubMed ID: 19444125
[TBL] [Abstract][Full Text] [Related]
19. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
20. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
